Lilly’s drug could cut the number of injections each patient needs by 85%.
The fill-finish site will produce both autoinjectors and pre-filled syringes – serving Roche’s pipeline and portfolio.
The agreement aims to accelerate the progression of the new multivalent enterovirus vaccine.
The collaboration will reach patients in the Central Susquehanna Valley, where WellSpan is investing in oncology services.
Pasatru demonstrated strong efficacy in a Phase III trial, helping patients reduce lesions and flare-ups.
The Novartis-backed biotech will now prepare for registrational studies on KYN-5356 in CIAS.
